Login
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

arcutis.com

What Do They Do?

Sells topical medicines for psoriasis, atopic dermatitis, and seborrheic dermatitis through healthcare providers to patients.

How Do They Make Money?

Most revenue comes from product sales to customers in the United States and Canada, counted when the products are delivered; other revenue primarily comes from licensing agreements.

revenue
SegmentShareRevenue
ZORYVE cream 0.3%
Sold outright

33%
FY2022: 100%
ZORYVE foam
Sold outright

49%
FY2022: 0.0%
ZORYVE cream 0.15%
Sold outright

18%
FY2022: 0.0%
ZORYVE cream 0.05%
Sold outright
0.2%

Who Are Their Customers?

Arcutis sells to wholesalers and specialty pharmacies in the United States and Canada, which resell its products to pharmacies, healthcare providers, and patients.

Do Revenues Turn Into Profits?

No. It lost $16.1M in FY2025.

Operating income, FY2025
−3% of revenue
▲ +90% (Loss) vs FY2024 (−$128.4M, −65%)
Net income, FY2025
−4% of revenue
▲ +88% (Loss) vs FY2024 (−$140M, −71%)
Free cash flow, FY2025
−2% of revenue
▲ +94% (Loss) vs FY2024 (−$112.3M, −57%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +45%
vs $99.2M in Q3 FY2025
Net income
▲ +19%
vs $7.4M in Q3 FY2025
ZORYVE foam share of product revenue, net vs 50.2% in Q3 FY2025
  • Aug 5, 2026 Raised full-year net product sales guidance The company raised its 2026 full-year outlook to $525 million–$540 million.

More products reached the market ZORYVE expanded from a psoriasis cream to include commercially launched foam and atopic-dermatitis creams; the older report described the foam and atopic-dermatitis cream as still in development.

Revenue over time
ZORYVE cream 0.3% ZORYVE foam ZORYVE cream 0.15% ZORYVE cream 0.05%
$500M$250M$0

Who Do They Compete With?

Competes with AbbVie, UCB, Amgen, Bristol Myers Squibb, Organon, Galderma Laboratories, Biocon, Johnson & Johnson, Protagonist Therapeutics, Meiji Pharma, UNION, Pfizer, Incyte, Arcotech, LEO Pharma, Sanofi, Regeneron Pharmaceuticals, Eli Lilly and, Apogee Therapeutics, and Nektar Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support